SCPC Provides Comments on CMS Proposed Rule Regarding Medicare Program
Dear Administrator Brooks-LaSure:
The Senior Care Pharmacy Coalition (SCPC) appreciates the opportunity to comment on the CMS Proposed Rule entitled “Medicare Program: Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefits Programs;” Agency Docket Number CMS-4192-P (the Proposed Rule).1 SCPC is the only Washington-based organization exclusively representing the interests of long-term care (LTC) pharmacies. SCPC’s membership includes 80% of all independent LTC pharmacies. Our members serve one million residents daily in skilled nursing facilities and assisted living communities across the country.2 Given the distinct characteristics of the LTC patient population and the enhanced clinical responsibilities of LTC pharmacies, we offer unique perspectives on CMS’ initiatives and proposals, particularly how Medicare Prescription Drug Benefit (“Part D”) policies and requirements impact the pharmacy community.
SCPC’s comments focus on the CMS “pharmacy price concessions to drug prices at the point of sale” proposal, which would require all “Direct and Indirect Remuneration” (DIR) fees charged to pharmacies by Part D Plans (PDPs) or their Pharmacy Benefit Managers (PBMs) be passed through to beneficiaries at the point of sale. 87 Fed Reg. at 1845, 1909. We believe that CMS should eliminate DIR fees rather than require that PDPs/PBMs pass them on to beneficiaries at point of sale. Should CMS nonetheless proceed with the proposal, the agency should assure that implementation does not inadvertently damage pharmacies and should prevent PDPs/PBMs from shifting any economic losses they sustain to pharmacies. Our comments explain these conclusions.
Click here to read the full letter.
Recent Posts
-
Rosenbloom: Curb PBMs’ power
Despite the purported value of pharmacy benefit managers (PBMs), drug prices remain unaffordable for many Americans (“Prescription drug pricing reform must rein in pharmacy benefit managers,” Web, Oct. 18). As middlemen between the manufacturers, pharmacies and consumers, PBMs are notorious for abusive business practices that impact both patients’ wallets and their access to prescription drugs, while gouging unaffiliated pharmacies.
-
Prescription Drug Middleman Potentially Profiting off Veterans
One of the three dominant U.S. pharmacy benefit managers (PBMs)—the middlemen that handle the vast majority of prescription drug plans in the United States—has instituted a scheme that has left roughly 400,000 active-duty and retired military households scrambling for a new pharmacy provider within the next week. Critics say the maneuver is a naked attempt by Express Scripts, the Cigna-owned PBM, to steer beneficiaries toward its own market-leading mail-order pharmacy.
-
The surprising group that will be hit hard by drug pricing reform
By Rachel CohrsSTAT Obviously, pharmaceutical companies are upset that they’re going to lose money from Medicare under Democrats’ new drug pricing law. But there’s another, less obvious group that’s concerned as well — long-term care pharmacies that serve almost entirely Medicare patients, and dispense the drugs that will likely enter the price negotiation program first. […]
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.